Biden administration to impose inflation penalties on dozens of drugs
Reuters
Published Dec 14, 2023 06:40AM ET
Updated Dec 14, 2023 05:16PM ET
By Andrea Shalal
BETHESDA, Md. (Reuters) -The Biden administration said on Thursday it had identified 48 drugs in the Medicare program whose prices rose quicker than inflation during the fourth quarter of the year and may require their makers to pay rebates.
President Joe Biden's signature Inflation Reduction Act (IRA) includes a provision to penalize drugmakers who work with Medicare, a government program for people aged 65 and older or who are disabled.
The 48 drugs it identified fall under Medicare Part B, which covers treatments administered at a health facility.
Medicare recipients could benefit by a reduction in their co-insurance payment for any of the drugs by $1 to $2,786 per average dose, according to a government statement.
The president, in remarks at the National Institutes of Health, said big pharmaceutical companies, in the year before the law was passed, "jacked up" prices nearly four times faster than inflation went up.
"They're ripping off Medicare. They're ripping off the American people," Biden said. "We're going to save taxpayers money and discourage companies from raising prices in the first place."
The White House is eager to emphasize the benefits of the IRA in bringing drug prices down ahead of the 2024 election, when Biden, 81, is running for a second term.
In total, prices of 64 drugs increased faster than inflation over the last four quarters, the White House said in a statement.
The IRA aims to save $25 billion annually by 2031 by requiring drugmakers to negotiate the prices of selected expensive drugs with the U.S. Centers for Medicare and Medicaid Service, which oversees Medicare.
The Biden administration last week announced it would create guidelines for when and how it could seize patents for medicines developed with government funding, including considering when their prices are too high.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.